Gilead Sciences, Inc. which can be found using ticker (GILD) now have 25 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $119.00 and $67.00 and has a mean share price target at $81.49. (at the time of writing). Given that the stocks previous close was at $69.31 and the analysts are correct then there would likely be a percentage uptick in value of 17.6%. There is a 50 day moving average of $66.03 and the 200 day moving average is $73.95. The company has a market capitalization of 85.75B. The stock price is currently at: $68.83 USD
The potential market cap would be $100,821,221,170 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 191.19, revenue per share of $22.00 and a 10.5% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
